Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
International journal of laboratory hematology - 43(2021), 1 vom: 19. Feb., Seite e48-e51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Evrard, Jonathan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dabigatran |
|---|
| Anmerkungen: |
Date Completed 21.06.2021 Date Revised 21.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ijlh.13356 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31607697X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31607697X | ||
| 003 | DE-627 | ||
| 005 | 20231225160311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ijlh.13356 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM31607697X | ||
| 035 | |a (NLM)33037773 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Evrard, Jonathan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2021 | ||
| 500 | |a Date Revised 21.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a dabigatran | |
| 650 | 4 | |a direct oral anticoagulants | |
| 650 | 4 | |a factor Xa inhibitors | |
| 650 | 4 | |a thrombin generation | |
| 650 | 4 | |a thrombolysis thresholds | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Thrombin |2 NLM | |
| 650 | 7 | |a EC 3.4.21.5 |2 NLM | |
| 700 | 1 | |a Hardy, Michaël |e verfasserin |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Lessire, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Maloteau, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Mullier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of laboratory hematology |d 2007 |g 43(2021), 1 vom: 19. Feb., Seite e48-e51 |w (DE-627)NLM167703048 |x 1751-553X |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2021 |g number:1 |g day:19 |g month:02 |g pages:e48-e51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ijlh.13356 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2021 |e 1 |b 19 |c 02 |h e48-e51 | ||